BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 36485090)

  • 21. Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
    Wang J; Jiang Q; Xu LP; Zhang XH; Chen H; Qin YZ; Ruan GR; Jiang H; Jia JS; Zhao T; Liu KY; Jiang B; Huang XJ
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):741-750. PubMed ID: 29247779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
    Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment Selection for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors.
    Ma Y; Zhang Q; Kong P; Xiong J; Zhang X; Zhang C
    Chemotherapy; 2019; 64(2):81-93. PubMed ID: 31390613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of allogeneic hematopoietic stem cell transplantation and TKI combined with chemotherapy for adult philadelphia chromosome positive acute lymphoblastic leukemia: a systematic review and meta-analysis.
    Zeng Q; Xiang B; Liu Z
    Cancer Med; 2021 Dec; 10(24):8741-8753. PubMed ID: 34761879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SOHO State of the Art Updates & Next Questions: Intensive and Non-Intensive Approaches for Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
    Short NJ; Kantarjian H; Jabbour E
    Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):61-66. PubMed ID: 34561201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The emerging use of chemotherapy-free regimens in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Sawyers JD; Jammal NJ; Short NJ; Kantarjian H; Jabbour EJ
    Clin Adv Hematol Oncol; 2023 Feb; 21(2):68-75. PubMed ID: 36780472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
    Ting S; Mixue X; Lixia Z; Xueying L; Wanzhuo X; Xiujin Y
    Ann Hematol; 2020 Apr; 99(4):829-834. PubMed ID: 32107574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prophylactic or preemptive tyrosine kinase inhibitor therapy after allogeneic hematopoietic cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Nakasone H
    Int J Hematol; 2023 Aug; 118(2):183-192. PubMed ID: 36807259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblast Leukemia: A Systematic Review.
    Warraich Z; Tenneti P; Thai T; Hubben A; Amin H; McBride A; Warraich S; Hannan A; Warraich F; Majhail N; Kalaycio M; Anwer F
    Biol Blood Marrow Transplant; 2020 Mar; 26(3):e55-e64. PubMed ID: 31557532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Giebel S; Czyz A; Ottmann O; Baron F; Brissot E; Ciceri F; Cornelissen JJ; Esteve J; Gorin NC; Savani B; Schmid C; Mohty M; Nagler A
    Cancer; 2016 Oct; 122(19):2941-51. PubMed ID: 27309127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study.
    Leotta S; Markovic U; Pirosa MC; Stella S; Tringali S; Martino M; Specchia G; Carluccio P; Risitano AM; Grimaldi F; Vigna E; Palmieri F; Palmieri R; Annunziata M; Pisapia G; Palazzo G; Milone GA; Pelle AC; Scalise L; Di Giorgio MA; Bulla A; Leotta V; Di Raimondo F; Milone G
    Ann Hematol; 2021 Jul; 100(7):1743-1753. PubMed ID: 33774681
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia.
    Hunger SP
    Hematology Am Soc Hematol Educ Program; 2011; 2011():361-5. PubMed ID: 22160058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.
    King AC; Pappacena JJ; Tallman MS; Park JH; Geyer MB
    Leuk Res; 2019 Apr; 79():27-33. PubMed ID: 30831480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Additional Cytogenetic Abnormalities in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
    Aldoss I; Stiller T; Cao TM; Palmer JM; Thomas SH; Forman SJ; Pullarkat V
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1326-9. PubMed ID: 25842050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Current management of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
    Onizuka M
    Rinsho Ketsueki; 2018; 59(10):2028-2035. PubMed ID: 30305505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia.
    Pavlovsky C; Chan O; Talati C; Pinilla-Ibarz J
    Future Oncol; 2019 Jan; 15(3):257-269. PubMed ID: 30251548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
    De Benedittis C; Papayannidis C; Venturi C; Abbenante MC; Paolini S; Parisi S; Sartor C; Cavo M; Martinelli G; Soverini S
    BMC Cancer; 2017 Aug; 17(1):523. PubMed ID: 28779753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Curing Ph+ ALL: assessing the relative contributions of chemotherapy, TKIs, and allogeneic stem cell transplant.
    Fielding AK
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):24-29. PubMed ID: 31808885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SOHO State of the Art Updates and Next Questions | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in Adults: Therapeutic Options and Challenges in 2023.
    Rahman ZA; Kebriaei P
    Clin Lymphoma Myeloma Leuk; 2023 Nov; 23(11):779-785. PubMed ID: 37438208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allogeneic transplantation for patients with Philadelphia chromosome positive acute lymphoblastic leukemia: Is it imperative in the tyrosine kinase inhibitor era?
    Litzow MR
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):357-360. PubMed ID: 30466747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.